Biological actions and therapeutic potential of the glucagon-like peptides

Gastroenterology

Volumn 122, Issue 2, 2002, Pages 531-544

  Drucker, Daniel J ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2;

APPETITE; CENTRAL NERVOUS SYSTEM; DRUG ACTIVITY; DRUG MECHANISM; GASTROINTESTINAL TRACT; HUMAN; INTESTINE INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; REVIEW;

EID: 0036158954     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.31068     Document Type: Article

References (172)

1. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem
2. Hamster preproglucagon contains the sequence of glucagon and two related peptides
3. Mammalian pancreatic preproglucagon contains three glucagon-related peptides
4. Preproglucagon messenger ribonucleic acid: Nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid
5. Glucagon gene expression in vertebrate brain
6. Proglucagon gene expression is regulated by a cyclic AMP-dependent pathway in rat intestine
7. Bioactive enteroglucagon (oxyntomodulin): Present knowledge on its chemical structure and its biological activities
8. Molecular evolution of proglucagon
9. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing
10. Identical mRNA for preproglucagon in pancreas and gut
11. Developmental and tissuespecific regulation of proglucagon gene expression
12. Trout and chicken proglucagon: Alternative splicing generates mRNA transcripts encoding glucagon-like peptide 2
13. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard
14. Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide
15. Proglucagon is processed to glucagon by prohormone convertase PC2 in aTC1-6 cells
16. Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2
17. Role of prohormone convertases in the tissue-specific processing of proglucagon
18. Proglucagon processing in an islet cell line: Effects of PC1 overexpression and PC2 depletion
19. Processing of mouse proglucagon by recombinant prohormone convertase 1 and immunopurified prohormone convertase 2 in vitro
20. Evidence for redundancy in propeptide/prohormone convertase activities in processing proglucagon: An antisense study
21. Molecular forms of human enteroglucagon in tissue and plasma: Plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract
22. Glucagon-like peptide-1 7-36: A physiological incretin in man
23. Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2)
24. Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients
25. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum
26. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion
27. Effects of fasting, refeeding and intraluminal triglyceride on proglucagon expression in jejunum and ileum
28. Dietary fiber modulates intestinal proglucagon messenger ribonucleic acid and postprandial secretion of glucagon-like peptide-1 and insulin in rats
29. Short-chain fatty acids increase proglucagon and ornithine decarboxylase messenger RNAs after intestinal resection in rats
30. Systemic short-chain fatty acids rapidly alter gastrointestinal structure, function, and expression of early response genes
31. Short-chain fatty acid-supplemented total parenteral nutrition alters intestinal structure, glucose transporter 2 (GLUT2) mRNA and protein, and proglucagon mRNA abundance in normal rats
32. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable
33. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum
34. Degradation of glucosedependent insulinotropic polypeptide and truncated glucagonlike peptide 1 in vitro and in vivo by dipeptidyl peptidase IV
35. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects
36. Glucagon-like peptide1-(7-36)amide is transformed to glucagon-like peptide-1-(936)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine
37. Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide 2
38. Regulation of the biological activity of glucagon-like peptide 2 by dipeptidyl peptidase IV
39. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans
40. In vivo and in vitro degradation of glucagon-like peptide-2 in humans
41. Renal catabolism of human glucagon-like peptides I and 2
42. Glucagonlike peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig
43. Enzymatic and renal-dependent catabolism of the intestinotropic hormone glucagonlike peptide-2 in the rat
44. Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1
45. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide peptice 1 receptor
46. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse
47. Human glucagonlike peptide-1 receptor gene: Localization to chromosome band 6p21 by fluorescence in situ hybridization and linkage of a highly polymorphic simple tandem repeat DNA polymorphism to other markers on chromosome 6
48. Non-linkage of the glucagon-like peptide 1 receptor gene with maturity onset diabetes of the young
49. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man
50. Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man
51. Amidated and non-amidated glucagon-like peptide-1 (GLP-1): Non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans
52. Examination of somatostatin involvement in the inhibitory action of GIP, GLP-1, amylin, and adrenomedullin on gastric acid release using a new SRIF antagonist analogue
53. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation
54. Rat parietal cell receptors for GLP-1-(7-36) amide: Northern blot, cross-linking, and radioligand binding
55. Comparative effects of GLP-1 (7-36)amide, oxyntomodulin and glucagon on rabbit gastric parietal cell function
56. Inhibition of human gastric lipase secretion by glucagon-like peptide-1
57. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
58. Sympathetic pathways mediate GLP-1 actions in the gastrointestinal tract of the rat
59. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow
60. Inhibitory effect of glucagon-like peptide-1 on small bowel motility
61. Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1
62. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (non-insulin dependent) diabetic patients
63. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
64. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line
65. Insulinotropin: Glucagon-like peptide 1 (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas
66. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut
67. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: Studies with the antagonist exendin 9-39
68. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide
69. Exendin(9-39)amide is an antagonist of glucagon-like peptide1(7-36)amide in humans
70. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene
71. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1(7-36) amide in type I diabetic patients
72. Glucose homeostasis in mice with disruption of GLP-1 receptor signaling
73. Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?)
74. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells
75. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells
76. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-l-positive pancreatic ductal cells into insulin-secreting cells
77. β-cell differentiation from a human pancreatic cell line in vitro and in vivo
78. Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase β-cell mass in mouse pancreas
79. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats
80. Glucagonlike peptide-1 and exendin-4 stimulates b-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age
81. Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice
82. A role for glucagonlike peptide-1 in the central regulation of feeding
83. Central administration of GLP-1(7-36) amide inhibits food and water intake in rats
84. Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats
85. Repeated intracerebroventricular administration of glucagon-like peptide1-(7-36) amide or exendin-(9-39) alters body weight in the rat
86. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats
87. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans
88. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2
89. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients
90. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
91. Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus
92. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: Evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake
93. Central infusion of GLP-1, but not leptin, produces conditioned taste aversion in rats
94. Glucagon-like peptide-1 (7-36) amide: A central regulator of satiety and interoceptive stress
95. A functional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia
96. Central infusion of glucagon-like peptide-1-(7-36)amide (GLP-1) receptor antagonist attenuates lithium chlorideinduced c-Fos induction in rat brainstem
97. Effects of aging and a high fat diet on body weight and glucose control in GLP-1R-/-mice
98. Development of glucagon-like peptide-l-based pharmaceuticals as therapeutic agents for the treatment of diabetes
99. Inhibition of the activity of dipeptidylpeptidase IV as a treatment for type 2 diabetes
100. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
101. CD26, let it cut or cut it down
102. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26
103. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats
104. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity
105. GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro
106. Biological activity of GLP-1-analogues with N-terminal modifications
107. The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients
108. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM
109. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes
110. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas
111. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure
112. Glucagon-Like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment
113. Induction of intestinal epithelial proliferation by glucagon-like peptide 2
114. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function
115. Plasma enteroglucagon after jejunoileal bypass with 3:1 or 1:3 jejunoileal ratio
116. Intestinal adaptation after jejunoileal bypass in man
117. Gut hormones in inflammatory bowel disease
118. The hormonal pattern of intestinal adaptation [a major role for enteroglucagon]
119. Expression of ileal glucagon and peptide tyrosine-tyrosine genes. Response to inhibition of polyamine synthesis in the presence of massive small-bowel resection
120. Nutrient-independent increases in proglucagon and ornithine decarboxylase messenger RNAs after jejunoileal resection
121. Ileal proglucagon gene expression in the rat: Characterization in intestinal adaptation using in situ hybridization
122. Increased ileal proglucagon expression after jejunectomy is not suppressed by inhibition of bowel growth
123. Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPB) bypass surgery for morbid obesity
124. Plasma enteroglucagon related to malabsorption in coeliac disease
125. Gut-hormone profile in coeliac disease
126. Gut hormone release after intestinal resection
127. Glucagonoma syndrome demonstrating giant duodenal villi
128. Villous hypertrophy of the small bowel in a patient with glucagonoma
129. Neglected radiologic signs of the glucagonoma syndrome
130. Trophic effects of glicentin on rat small-intestinal mucosa in vivo and in vitro
131. Proglucagon-derived peptides in intestinal epithelial proliferation: Glucagon-like peptide-2 is a major mediator of intestinal epithelial proliferation in rats
132. Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease
133. Structure, measurement, and secretion of human glucagonlike peptide-2
134. Intestinal response to growth factors administered alone or in combination with h[Gly2]-Glucagon-like peptide 2
135. Minimal enteral nutrient requirements for intestinal growth in neonatal piglets: How much is enough?
136. Impaired meal-stimulated glucagon-like peptide-2 response in ileal resected short bowel patients with intestinal failure
137. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon
138. Intestinal growth is associated with elevated levels of glucagon-like peptide-2 in diabetic rats
139. Diabetic intestinal growth adaptation and glucagon-like peptide 2 in the rat: Effects of dietary fibre
140. Intestinal growth-promoting properties of glucagon-like peptide 2 in mice
141. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice
142. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis
143. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2
144. Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo
145. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse
146. Glucagon-like peptide-2 increases sucrase-isomaltase but not caudal-related homeobox protein-2 gene expression
147. The effect of gastric inhibitory polypeptide and glucagon like peptides on intestinal hexose transport
148. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo
149. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2
150. Glucagonlike peptide-2 inhibits centrally induced antral motility in pigs
151. Prevention of parenteral nutrition-induced gut hyoplasia by coinfusion of glucagon-like peptide-2
152. Maintaining gut integrity during parenteral nutrition of tumor-bearing rats: Effects of glucagon-like peptide 2
153. GLP-2 augments the adaptive response to massive intestinal resection in rat
154. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacininduced murine enteritis
155. The effect of glucagon-like peptide 2 on intestinal permeability and bacterial translocation in acute necrotizing pancreatitis
156. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2
157. GLP-2alpha accelerates recovery of mucosal absorptive function after intestinal ischemia/reperfusion
158. Glucagonlike peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion
159. Human [Gly2]-GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis
160. Glucagon-like peptide 2: A new treatment for chemotherapyinduced enteritis
161. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor
162. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2
163. Enteroendocrine localization of GLP-2 receptor expression
164. Glucagon-like peptide-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling
165. Modulation of specific intestinal epithelial progenitors by enteric neurons
166. Identification of glucagon-like peptide-2 (GLP-2)activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor
167. Signaling mechanisms of glucagon-like peptide 2-induced intestinal epithelial cell proliferation
168. The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway
169. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon
170. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor
171. Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine
172. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake